HALT-D: a Randomized Open-Label Phase II Study of Crofelemer for the Prevention of Chemotherapy-Induced Diarrhea in Patients with HER2-positive Breast Cancer Receiving Trastuzumab, Pertuzumab, and a Taxane
Breast Cancer Research and Treatment(2022)
Key words
Trastuzumab,Pertuzumab,Chemotherapy-induced diarrhea,Taxane,Crofelemer,HER2-positive breast cancer
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined